Adaptive Biotechnologies ... (ADPT)

NASDAQ: ADPT · Real-Time Price · USD

7.37

0.01 (0.14%)

At close: May 01, 2025, 3:59 PM

7.36

-0.14%

After-hours: May 01, 2025, 04:20 PM EDT

0.14% (1D)

Bid	7.5
Market Cap	1.1B
Revenue (ttm)	178.96M
Net Income (ttm)	-159.49M
EPS (ttm)	-1.08
PE Ratio (ttm)	-6.82
Forward PE	-10.51
Analyst	Buy

Ask	7.97
Volume	1,636,025
Avg. Volume (20D)	2,033,996
Open	7.44
Previous Close	7.36
Day's Range	7.21 - 7.51
52-Week Range	2.74 - 9.01
Beta	1.73

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a cli...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 27, 2019

Employees 619

Stock Exchange NASDAQ

Ticker Symbol ADPT

Website https://www.adaptivebiotech.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 22.12% from the latest price.

Stock Forecasts

Earnings Surprise

New

Adaptive Biotechnologies has released their quartely earnings on May 1, 2025:

Revenue of $52.4M exceeds estimates by $10.27M, with 25.14% YoY growth.

EPS of -0.2 exceeds estimates by 0.11, with 39.39% YoY growth.

Next Earnings Release

Adaptive Biotechnologies Corporation is scheduled to release its earnings on May 1, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-0.52%

Adaptive Biotechnologies shares are trading higher... Unlock content with Pro Subscription

2 months ago

-3.21%

Adaptive Biotechnologies shares are trading lower. The company reported Q4 financial results.

News

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Fou...

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to ...

2 months ago · zacks.com

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.